Clinical trials
No Disease or Condition is Being Studied clinical trials
Below are recruiting no disease or condition is being studied clinical trials, each written for real people, not researchers. We’re tracking 18,404 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07419334RecruitingPhase 3
Study of a new drug for Stargardt disease
This trial tests a new drug, ALK-001, to see if it can slow down vision loss from Stargardt disease. It is for people who have a confirmed genetic diagnosis and are between 8 and 45 years old.
Phoenix, ArizonaAges 8–45 - NCT07418736RecruitingPhase 2
CM326 for moderate to severe COPD
This trial tests a new medicine called CM326 for people with moderate to severe COPD. It aims to see if the drug can reduce flare-ups and improve lung function.
Beijing, Beijing MunicipalityAges 40–85 - NCT07419828RecruitingPhase 3
Study of HRS-1780 for chronic kidney disease
This trial tests an investigational drug called HRS-1780 in people with chronic kidney disease. It aims to see if the drug can help slow kidney decline and is safe to use.
Nanjing, JiangsuAges 18–80 - NCT06817434Recruiting
Statin treatment for Moyamoya disease study
This study tests if statins (cholesterol-lowering drugs) can help people with Moyamoya disease. The trial will follow patients who receive either surgery or standard care to see if adding a statin improves outcomes.
Beijing, ChinaAges 18–60 - NCT07420023Recruiting
Nutrition study for weight management and fullness
This study tests a special food product and meal plan to help people feel fuller longer and control appetite. It may help you understand how certain foods affect your body and weight.
CorkAges 18–45 - NCT07407816Recruiting
Supira heart support device for high-risk artery stenting
This trial tests a new device (the Supira system) that helps support your heart's pumping function during and after a high-risk procedure to open blocked coronary arteries. It is for people with heart failure and complex blockages who may need extra circulatory support.
Tbilisi, K'alak'i T'bilisiAges 18–90 - NCT07412691RecruitingPhase 1
Safety study of BG-A3004 in healthy people and skin disease patients
This study tests a new drug (BG-A3004) for safety in healthy volunteers and people with certain skin conditions like alopecia areata, cutaneous lichen planus, or vitiligo. It helps find out if the drug is safe and how the body processes it.
Beijing, Beijing MunicipalityAges 18–60 - NCT07408336RecruitingEarly Phase 1
Study of AFN50 injection for active lupus
This study tests an investigational injection called AFN50 for people whose lupus (SLE) remains active despite standard treatments. The goal is to see if the drug can safely help control lupus symptoms better than current therapies alone.
Hefei, AnhuiAges 18–69 - NCT07404111RecruitingPhase 1/Phase 2
Study of VV-14305 for thyroid eye disease
This study tests an investigational medication for thyroid eye disease, which causes bulging eyes and discomfort. The treatment is given as an injection near the eye, and the study will last about 12 months to see how safe and effective it is.
Livonia, MichiganAges 18–80 - NCT07403968RecruitingPhase 2
Study of Zasocitinib for Active Crohn's Disease
This trial tests a new oral medicine called Zasocitinib for people with active Crohn's disease who have tried other treatments that no longer work or are not tolerated. The goal is to see if it can reduce inflammation and improve symptoms.
OxfordAges 18–75 - NCT07399171RecruitingPhase 2
Testing HT-4253 to prevent Alzheimer's in APOE4 carriers
This trial tests an experimental drug called HT-4253 to see if it can prevent Alzheimer's disease in people who are at higher genetic risk (carry the APOE4 gene) and have early signs of amyloid buildup in the brain. If you qualify, you would take the drug or a placebo and be monitored over time.
Abu Dhabi, Abu Dhabi EmirateAges 50–75 - NCT07404644Recruiting
Study of vonicog alfa in children with von Willebrand disease
This study looks at how well vonicog alfa (a lab-made version of a missing blood protein) works to control bleeding in children under 18 with von Willebrand disease. It follows children who are already prescribed this treatment in Japan to see how safe and effective it is in real life.
Tokyo, TokyoAges Up to 17 years - NCT07401823Enrolling by invitationPhase 2
Long-term follow-up study for sickle cell disease treatment
This study is a follow-up for people with sickle cell disease who already saw a benefit in fetal hemoglobin from the earlier Pioneer study. It tests the long-term safety and effects of the study drug pociredir (also called FTX-6058) while allowing most standard sickle cell treatments except hydroxyurea.
Little Rock, ArkansasAges 18 years+ - NCT06162338Recruiting
Study of LY-M001 for Gaucher Disease Type I
This study tests an injection called LY-M001 for adults with Gaucher disease type I. The goal is to see if it can safely help replace the missing enzyme and improve symptoms.
Hanzhou, ZhejiangAges 18–60 - NCT07399002Recruiting
Long Nagomi stent study for heart artery blockages
This trial tests a new long stent (Ultimaster Nagomi) for treating long blockages in the heart arteries. It aims to see how well the stent works in real-world patients who need a single stent for a long lesion.
CabueñesAges 18 years+ - NCT07406932Recruiting
JAK inhibitors vs standard therapy for lung scarring in Anti-Synthetase Syndrome
This trial tests whether a new class of drugs called JAK inhibitors (which block inflammation signals) is better than a standard treatment (calcineurin inhibitors) for people with lung scarring (interstitial lung disease) caused by Anti-Synthetase Syndrome. It is for people who have not yet taken any immune-suppressing medications for this condition.
Beijing, Beijing MunicipalityAges 18–75 - NCT06323538Recruiting
Plant-based diets and health (COPLANT)
This study looks at how different plant-based diets affect your health. Researchers will collect information through questionnaires and blood samples to understand the benefits of eating more plants.
ViennaAges 18–69 - NCT07392411Recruiting
AI study of face and speech in Parkinson's disease
This study uses artificial intelligence to analyze facial expressions and speech patterns in people with Parkinson's disease, multiple system atrophy, or progressive supranuclear palsy. The goal is to find digital markers that may help track the disease.
Beijing, Beijing MunicipalityAges 15–75 - NCT07397390Enrolling by invitation
Study of a new scoring balloon for leg artery blockages with heavy calcium buildup
This study tests a new balloon device that scores the artery walls to treat leg artery blockages with heavy calcium deposits. It aims to see if the device helps prepare the vessel safely and effectively before placing a stent.
Dalian, LiaoningAges 18–85 - NCT06832839Recruiting
Cognitive impairment in moyamoya disease study
This study looks at why some people with moyamoya disease have trouble with thinking and memory. It may help find better ways to understand and treat these problems.
Beijing, ChinaAges 18–60 - NCT07380737Recruiting
Walking Tall app for home exercise in Parkinson's
This study tests a smartphone app called Walking Tall that helps people with Parkinson's disease do walking exercises at home. It's looking for people who can walk on their own and are already in a specific rehab program.
Tel AvivAges 40–85 - NCT07382258Recruiting
Inhaled nitric oxide for COPD: a clinical study
This trial tests whether a gas called nitric oxide, breathed in through the nose or mouth, can help people with moderate to severe COPD. It could improve breathing and quality of life.
Nanjing, JiangsuAges 40–75 - NCT07386418Recruiting
Angina thresholds study for patients needing stent treatment
This trial is testing a new way to measure blood flow in the heart during exercise to better understand angina. You may be eligible if you have at least two blocked heart arteries and are scheduled for stent placement.
BasildonAges 18 years+ - NCT06837272Recruiting
Gut health and brain health in Alzheimer's disease
This study looks at how the bacteria in your gut might be connected to memory and thinking problems in Alzheimer's disease. It may help us understand if changes in the gut can affect brain health.
Jining, ShandongAges 60–80
Hear when a new No Disease or Condition is Being Studied trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for no disease or condition is being studied?
- Yes. Clin2 currently lists 18,404 recruiting no disease or condition is being studied studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a no disease or condition is being studied trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a no disease or condition is being studied trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.